MetabolicKEDWLys-Glu-Asp-Trp

Pancragen (KEDW)

Khavinson 'Cytogen' synthetic tetrapeptide · claimed pancreas/glucose bioregulator · single-school evidence

Pancragen is a synthetic tetrapeptide — four amino acids, Lys-Glu-Asp-Trp (KEDW) — from the 'Cytogen' line of short 'peptide bioregulators' developed by Vladimir Khavinson and the St. Petersburg Institute of Bioregulation and Gerontology in Russia. Within that family it is positioned as the 'pancreas' peptide, marketed for blood-sugar control and pancreatic function, especially in aging. The chemistry of the KEDW tetrapeptide is real and verifiable. The biology comes with the usual caution for this family: essentially all of the experimental evidence is from Khavinson's network and its immediate circle — including monkey glucose-tolerance studies (Goncharova), pancreatic-morphology work (Kvetnoi), and a human-oriented elderly-metabolism paper (Korkushko). One partial exception is a separate Russian lab (Vanyushin's group) that reported the peptide can bind DNA and histones — but that corroborates only molecular binding, not pancreatic efficacy. There is no Western or independent randomized replication of the glucose or pancreatic effects. The proposed mechanism — that this small peptide binds DNA directly and regulates genes — is a single-school hypothesis, not mainstream-established science. The fair framing: a well-defined little molecule with a pancreas/glucose research story built almost entirely by one school in small animal, primate and review studies — biologically interesting, but unproven in controlled human trials and not approved anywhere.

The short version

Pancragen is a trade name for KEDW, a synthetic peptide of four amino acids (lysine, glutamic acid, aspartic acid, tryptophan). It comes from the Russian 'Cytogen' family of tiny 'bioregulator' peptides designed by Vladimir Khavinson's group, where each peptide is assigned a target tissue. Pancragen's assigned tissue is the pancreas — the organ that makes insulin and controls blood sugar.

The molecule is real and well-defined chemically. The harder question is whether its pancreas and blood-sugar claims hold up. Nearly all the experimental evidence comes from Khavinson's network and the labs closest to it — studies in rats with experimental diabetes, in aging monkeys, and a paper on metabolic problems in elderly people. A separate Russian lab did report that the peptide can stick to DNA and histones, but that only shows the molecule binds something in a test tube; it does not show it helps the pancreas.

Crucially, no independent or Western team has run a proper randomized trial confirming the glucose or pancreatic benefits. And the headline mechanism — that this little peptide binds DNA and switches genes on and off — is a single-school idea, not something mainstream molecular biology has established. So Pancragen is best understood as an experimental peptide with a pancreas/glucose research story built almost entirely by one school — interesting, but unproven in people and not approved as a medicine.

Molecular identity

Specs

Monoisotopic mass: 576.2544 Da (free acid)

Sequence (4 AA): Lys-Glu-Asp-Trp (KEDW), free acid (all-L)PubChem CID 68452877
Structure / class: Synthetic tetrapeptide; Khavinson 'Cytogen' bioregulatorPubChem CID 68452877; Khavinson-school literature
Molecular formula: C₂₆H₃₆N₆O₉PubChem CID 68452877 (free-acid KEDW)
Molecular weight: 576.6 g/molPubChem CID 68452877 (free-acid KEDW)
Form note: Free-acid identifiers shown; part of the literature describes the bioactive endogenous form as the C-terminal amide KEDW-NH₂ (different exact mass) — flagged, not asserted herePMID 21246099 (KEDW-NH₂) vs PubChem free-acid CIDs
PubChem CID: 68452877 (all-L); 18304372 (flat / undefined stereo)PubChem
CAS / UNII: Unverified — not assertedNo CAS or UNII in PubChem registry xrefs for CID 68452877
Water solubility: Water-soluble (polar free-acid tetrapeptide; lone Trp residue adds some hydrophobicity; reconstituted in bacteriostatic water)Structural inference (ionizable Lys/Glu/Asp side chains)
Molecular target: No classic receptor identified; claimed pancreas/islet gene-expression modulator — glucose handling (single-school positioning)Khavinson-school 'tissue-specific peptide' framework (not independently established)
Half-life: Not established (no published human pharmacokinetics)Not established
Regulatory status: Not approved by any major drug regulator; no Western/independent randomized trials locatedNo NDA/BLA/EMA record located

Plain English

Mechanism

The Khavinson school's proposal — applied to Pancragen and the whole Cytogen family — is that ultra-short peptides like KEDW penetrate cells and the nucleus, bind specific DNA promoter sequences or histones, and act as direct gene-expression regulators ('peptidergic regulation of gene expression'), tissue-specifically restoring function in aged cells. For Pancragen the claimed target is pancreatic and islet cells, and the downstream effect is better glucose handling.

This needs a plain caveat: the gene-regulation-via-direct-DNA-binding mechanism for a free tetrapeptide is a single-school hypothesis. It is not established or replicated in mainstream molecular biology, and it should be treated as claimed, not demonstrated.

What has actually been shown at the molecular level is limited to binding assays: molecular-mechanics modelling of DNA–tetrapeptide interactions from the Khavinson group, and DNA/histone-binding work from a separate Russian lab (Vanyushin's group, reporting binding to FITC-labelled histones and oligonucleotide complexes). These show that the peptide can interact with DNA/histones — but not a validated downstream gene-regulatory mechanism in pancreatic tissue. The leap from 'binds DNA in vitro' to 'restores pancreatic gene expression and glucose control in a living animal or person' is exactly where the evidence becomes hypothesis.

Sources:PMID 21246099 PMID 23581987 PMID 24770759 PMID 27909961

Why people reach for it

Potential benefits

Pancragen is the 'pancreas' peptide of the Khavinson Cytogen line — here is what draws people to it, kept honest about a single-school, unproven evidence base.

The pancreas/blood-sugar slot in a Khavinson routine — Pancragen is the Cytogen line's pancreas-assigned tetrapeptide, so people building a tissue-by-tissue bioregulator protocol reach for it as the metabolic piece — a positioning, not a demonstrated human effect.
A glucose-handling research story in aging — Its most-developed evidence is glucose-tolerance and pancreatic-morphology work in experimental-diabetes rats and aged monkeys, which is why it's reached for around age-related metabolic decline — though that data is animal/primate and single-school.
A genuinely well-defined little molecule — Unlike several products in this family, KEDW (Lys-Glu-Asp-Trp) is a real, chemically verifiable tetrapeptide — part of the appeal is that you at least know what the molecule is, even if its biology is unproven.
Pairs with the proven metabolic levers — It is most defensibly used as a complement to the things that actually move glucose — diet, exercise, and well-evidenced aids like berberine and alpha-lipoic acid — rather than as a substitute for them.
Short, course-based, low-burden — Run as brief pulsed courses rather than continuous use, it asks little of the user — appealing to people already invested in the Khavinson approach to longevity.

Sources:PMID 18642713 PMID 18225766 PMID 25946840 PMID 22448364

What people reach for Pancragen for, drawn from its positioning and the single-school research (animal, primate and review studies) — not proven human outcomes or medical claims. It is not a treatment for diabetes or any condition.

Implied timing

Best time to dose

Implied best time

Anytime (consistent, with food)

Time of day isn't critical for Pancragen — pick a consistent daily time, and taking it with a meal is a sensible convention given its metabolic target.

Pancragen has no published human pharmacokinetics and no half-life on record, so there is no clearance curve to time a dose against — day-to-day consistency matters more than the exact hour.
Because its claimed target is the pancreas and glucose handling, pairing the dose with a meal is a reasonable habit — it lines the compound up with the digestive/metabolic activity it is positioned to support. This is convention, not a studied schedule.
If it is run alongside other Khavinson-family peptides, fixing it to the same daily mealtime each day is the simplest way to keep the course consistent.

No study establishes an ideal time of day for Pancragen — this is reasoned from its metabolic positioning and how it's used, not from data. As a rule of thumb most peptide dosing lands in the midday-to-evening window; for Pancragen any consistent time works, with a mild lean toward taking it with a meal.

Sources:PMID 18642713 PMID 25946840

How to run it

Dosing & protocol

Pancragen is dosed here as a subcutaneous injection — the form sold as a research peptide and the route the on-page calculator is built for. There is no established human dose: no human clinical trial has been published, so every number below is vendor-and-community convention, extrapolated from the Khavinson animal and primate studies. Read it as a map of how people actually run injectable Pancragen — not a validated prescription.

Single-school, no human dose: Pancragen has no human clinical trial and no peer-reviewed human dosing regimen. Its entire efficacy evidence comes from Khavinson's network in animal, primate and review studies. Every number here is community convention, not trial data, and it is not an FDA-approved drug.

Dose — no established human dose

Convention in the absence of trial data: vendor-circulated amounts for injectable KEDW.

Conventional range:: 500–1,000 mcg per dose, once daily — the range most often cited in gray-market vendor guides and community protocols. The lower end is typically used first to assess individual tolerance; the upper end for what vendors describe as 'therapeutic' courses.
Route:: Subcutaneous injection, same as other Khavinson-family research peptides.
Important caveat:: Part of the literature (PMID 21246099) describes the bioactive endogenous form as the C-terminal amide KEDW-NH₂ — a different exact mass from the free-acid KEDW in the specs above. Vendors rarely disclose which form they are selling. The dose you draw may not be the form the binding studies used; this ambiguity is real and worth knowing before you run a course.

Subcutaneous administration

Pancragen is injected into subcutaneous fat; site rotation and timing are the actionable choices.

Injection site:: The abdomen (staying a couple of inches clear of the navel), the love-handle area, or the outer thigh. Rotate sites across doses — using the same spot repeatedly causes local irritation and lipohypertrophy (small fatty lumps under the skin).
Measuring the dose:: Drawn on a U-100 insulin syringe from the reconstituted vial. At the standard mix (10 mg vial + 2 mL bacteriostatic water = 5,000 mcg/mL): 500 mcg = 10 IU · 750 mcg = 15 IU · 1,000 mcg = 20 IU. The on-page calculator handles any vial size.
Time of day:: No published circadian rationale exists for Pancragen specifically — see Best time to dose above. Time of day isn't critical; a consistent daily time matters more than the exact hour, and pairing the dose with a meal is a sensible convention given its pancreatic/metabolic target.
Food window:: Subcutaneous injection bypasses digestive breakdown entirely, so there is no food window restriction.

Cycle & washout

The Khavinson family is conventionally run as pulsed courses rather than indefinite daily use.

Standard course:: 10–30 days of daily injection — matching the 'peptide bioregulator' course model described in the Khavinson literature (though those publications describe unspecified oral or parenteral doses in animal models, not a human SubQ schedule).
Washout:: 1–3 months off between courses is the community convention. If you are running Pancragen alongside other Khavinson-family peptides (Epithalamin, Cortagen, etc.) the same course-and-rest logic applies to each.
No chronic daily use:: There is no long-term safety data for continuous Pancragen use. Community convention keeps it to defined courses; indefinite daily dosing is outside even the single-school evidence base.

Reconstitution at a glance

The on-page calculator does this live; the quick reference for a 10 mg vial:

Mixing:: 10 mg vial + 2 mL bacteriostatic water = 5,000 mcg per mL. On a 100-unit (1 mL) insulin syringe: 500 mcg = 10 IU · 750 mcg = 15 IU · 1,000 mcg = 20 IU.
Why 2 mL:: The standard mix keeps dose volumes in a comfortable 10–20 IU range on a U-100 syringe — measurable without microscopic precision. The calculator adjusts for any dilution you prefer.

Sources:PMID 18642713 PMID 18225766 PMID 25946840 PMID 22448364

Substrate the signal needs

Nutritional cofactor precision

Pancragen is positioned as a pancreas / glucose-metabolism bioregulator, so the useful cofactors are the inputs that actually govern blood-sugar handling. Three questions applied to its proposed target: what amplifies the glucose-handling machinery, what proven levers exist that Pancragen cannot match, and what does glucose metabolism consume that needs supplying? Every card is reasoned from glucose physiology — not a Pancragen cofactor study.

Reasoned from Pancragen's proposed pancreatic/glucose-metabolism target — not a cofactor trial. Critical honest note: diet, exercise, and the supplements below are the better-evidenced levers for glucose control; Pancragen's own metabolic effect is a single-school, unproven hypothesis. None of this is a treatment for diabetes or any other condition.

The proven glycemic levers — diet & exercise (foregrounded)

These do more for blood sugar than any peptide with thin single-school evidence.

Diet composition:: Steadier blood glucose tracks with high fiber intake, adequate protein, and minimizing refined carbohydrate and added sugar — this is the single largest controllable lever for glucose metabolism and has decades of randomized-trial support. If the interest is the pancreas/glucose angle, this is where the real, well-established leverage lives.
Exercise:: Resistance training and aerobic activity both increase insulin sensitivity acutely and chronically — another lever with far stronger evidence than any Khavinson bioregulator. Aim for at least 150 minutes of moderate-intensity activity weekly plus 2 strength sessions.

Amplify — glucose-handling minerals (chromium · magnesium)

Two micronutrients directly involved in insulin signaling and glucose uptake.

Chromium:: 200 mcg chromium picolinate daily — chromium potentiates insulin's action at the receptor level (the chromodulin pathway); deficiency is associated with impaired glucose tolerance. This is Pancragen's proposed downstream territory, so chromium amplifies the pathway from a well-established direction.
Magnesium:: 300–400 mg magnesium glycinate or malate daily, taken with food — magnesium is required for glucose transporter activity and insulin receptor signaling; low magnesium is consistently associated with insulin resistance in population studies. Timing with a meal reduces the laxative effect.

Amplify — the best-evidenced glycemic nutraceuticals (ALA · berberine)

Two compounds with meaningful randomized-trial evidence for glucose control — stronger levers than Pancragen by a wide margin.

Alpha-lipoic acid (ALA):: 600 mg alpha-lipoic acid daily (or 300 mg twice daily), taken 30 minutes before a meal — ALA is the best-evidenced glycemic nutraceutical, with multiple RCTs showing improvements in insulin sensitivity and fasting glucose; it also acts as a potent mitochondrial antioxidant, relevant to the metabolically-stressed pancreas. The 30-min pre-meal window maximizes glucose uptake effect.
Berberine:: 500 mg berberine HCl three times daily with meals — berberine is the single strongest natural glucose-lowering agent in randomized trials, activating AMPK (the cellular energy sensor that improves insulin sensitivity) by a mechanism similar to metformin. It is a proven lever; Pancragen is an unproven one. Note: berberine interacts with some medications; anyone on glucose-lowering drugs should not combine without medical oversight.

Mitigate — glucose awareness

Monitoring, not a supplement — but the most actionable item on this list.

Blood glucose monitoring:: If running Pancragen for a glucose/metabolic goal, a basic glucose meter (fasting + 2-hour post-meal readings) gives real signal: you will know whether anything is moving the needle, and you will catch unexpected hypoglycemia from the combination of berberine + any other glucose-lowering agent. This is not optional if you are stacking active glycemic compounds.

Supply — adequate protein

The pancreas secretes enzymes; the body rebuilds tissue; both require amino acid substrate.

Protein intake:: 1.6–2.0 g per kg of bodyweight daily from whole food sources — sufficient protein intake maintains the amino acid pool the body needs for pancreatic enzyme synthesis, tissue maintenance, and general metabolic function. This is a supply-the-substrate cofactor, not a glucose-specific one, but it anchors everything else.

Combinations + timing

Stacking notes + timing windows

Pancragen's proposed job is pancreatic and glucose-metabolism bioregulation — within the Khavinson 'one peptide per tissue' framework. The natural pairing logic is either other Khavinson-family bioregulators (the whole-system longevity approach) or metabolic peptides that approach glucose from a different angle. Both carry an additional layer of honesty.

Community convention, doubly unproven: (1) Pancragen itself has no human trial; (2) stacking single-school Khavinson bioregulators with each other multiplies the speculation — it combines unproven things, not validated synergies. The free-acid-vs-amide ambiguity (KEDW vs KEDW-NH₂) also applies to every 'Pancragen' in these stacks — you may not be dosing the same form the binding studies used. Read every pairing here as reasoned-from-positioning, not tested.

Pancragen + Epithalamin (Epitalon) — the Khavinson longevity pair

The two most-discussed Khavinson bioregulators combined — pancreas + pineal gland.

Why it works (proposed):: Epithalamin (Epitalon) is the Khavinson 'pineal' peptide (Ala-Glu-Asp-Gly), studied for telomerase activation and circadian/melatonin regulation. Pairing it with Pancragen follows the family's own logic: each tissue gets its bioregulator, and the pineal gland governs the circadian rhythm that coordinates metabolic timing — so the reasoning is that supporting both the sleep-wake axis and the pancreatic signal is more complete than either alone.
The protocol:: Both run on the same course-and-rest model. Convention: Pancragen 500–1,000 mcg SubQ daily + Epitalon on its own typical schedule (commonly 5–10 mg/day SubQ for a 10-day course), run concurrently. The same course-length and washout pattern applies to both.
Outcome:: Reached for by users running a Khavinson longevity course targeting multiple systems simultaneously. The stacking-multiplies-speculation caveat applies fully: two unproven peptides combined.

Pancragen + Cortagen — pancreas + cardiovascular Khavinson pair

Adding the 'heart/vessel' Khavinson tetrapeptide to the 'pancreas' one.

Why it works (proposed):: Cortagen is the Khavinson-assigned cardiovascular bioregulator (Ala-Glu-Asp-Arg). Cardiovascular risk and glucose dysregulation are tightly linked — the pairing follows the same multi-tissue logic. No interaction data exist; this is the family's own internal convention applied to two related organ systems.
The protocol:: Pancragen 500–1,000 mcg + Cortagen 500–1,000 mcg SubQ daily, run as concurrent courses with the same 10–30-day duration and washout window.
Outcome:: The combination users reach for in a metabolic + cardiovascular context. Treat as community convention from within the Khavinson framework — not validated independently.

Pancragen + Semaglutide / GLP-1 analogs — metabolic approach from a different angle

Pairing the unproven Khavinson peptide with the best-evidenced glucose intervention.

Why it works (proposed):: GLP-1 receptor agonists (semaglutide, liraglutide) act on the incretin axis — stimulating insulin secretion, suppressing glucagon, and slowing gastric emptying — which is a mechanistically different route to glucose control than Pancragen's claimed intranuclear gene-regulation. Different levers on the same system. This pairing is primarily conceptual; there is no head-to-head data.
The protocol:: GLP-1 agonist on its prescribed schedule; Pancragen 500–1,000 mcg SubQ daily on a separate course. Critical note: GLP-1 agonists are approved medications with known drug-interaction profiles; adding any unapproved research peptide alongside them is uncharacterised. Anyone on a GLP-1 for diabetes or metabolic disease should not add Pancragen without medical oversight.
Outcome:: A thematic pairing for users already on a GLP-1 who want to add the Khavinson-family element. The honest position: GLP-1 agonists have robust RCT evidence; Pancragen does not. The value-add of Pancragen in this stack is entirely speculative.

Reconstitution math

Reconstitution calculator

Calculated for a 1 mL U-100 insulin syringe (100 units/mL).

Peptide per vial

BAC water added

Desired dose

Units per dose

Draw to this mark on a U-100 syringe

Volume per dose: 0.2 mL
Doses per vial: 10
Concentration: 5 mg/mL

One vial lasts

Daily: 10 days
Every other day: 20 days
5×/week: 14 days

Research use only. Not for human consumption. Outputs are reference values based on research literature — verify all measurements independently.

From the studies

Side effects from research

There is no meaningful human safety database for Pancragen. The research is animal, primate and cell/review work, which cannot characterise side effects, rare events, or long-term risk in people. Absence of reported harm in such studies is not the same as a demonstrated safety profile.

Because the claimed effects involve blood sugar, the lack of controlled human safety data is particularly relevant for anyone with diabetes or glucose-regulation problems — there is no reliable evidence about how it behaves in people at any dose or duration.

Gray-market sourcing adds purity and identity risk independent of the peptide. The honest summary: Pancragen's human safety is uncharacterised, not established.

Sources:PMID 18642713

As reported in literature

Research dosing ranges

These are experimental designs from animal, primate and review studies — all from the Khavinson network and its immediate circle — shown for reference only. There is no human dose, no approved regimen, and no independent randomized replication. Read the table for what was actually tested (rats, monkeys) versus what is claimed (human blood-sugar control): that gap is the story.

Dose	Route	Model	Outcome	Sources:
In vivo	In vivo (rats)	Rats with experimental diabetes (Khavinson 2007, Bull Exp Biol Med)	Reported effects on blood glucose, capillary permeability and adhesion in experimental diabetes — an animal-model metabolic signal, not a clinical outcome	PMID 18642713
In vivo	In vivo (rats)	Pancreatic functional morphology in experimental-diabetes rats (Kvetnoi 2007, Bull Exp Biol Med — as 'pancragene')	Reported effect on the functional morphology of the pancreas — a tissue-level animal signal	PMID 18225766
In vivo	In vivo (primates)	Old female rhesus monkeys with impaired glucose tolerance (Goncharova 2014/2015, Advances in Gerontology)	Reported impact on endocrine pancreatic function and correction of impaired glucose tolerance in aged monkeys — a primate-model signal from a network lab, not an independent human trial	PMID 25946840
Not specified	Human-oriented review	Elderly people, metabolic-disorder correction 'prospects' (Korkushko 2011, Bull Exp Biol Med)	Discusses prospects for correcting metabolic disorders in the elderly — framed as prospects, with no verifiable controlled dosing regimen; treat as a single-school, human-oriented review, not trial evidence	PMID 22448364

Quick answers

Frequently asked

What is Pancragen?

It is a trade name (also 'Pancravit') for KEDW, a synthetic tetrapeptide (Lys-Glu-Asp-Trp) from Vladimir Khavinson's Russian 'Cytogen' line of short peptide bioregulators, positioned as the 'pancreas' peptide for blood-sugar and pancreatic function. The molecule is well-defined chemically; the metabolic claims are single-school and unproven.

Does Pancragen improve blood sugar or pancreatic function?

That is not established in people. The evidence is animal (experimental-diabetes rats), primate (aging monkeys with impaired glucose tolerance), and single-school reviews — all from Khavinson's network or its immediate circle, with no independent or Western randomized trial. Treat the glucose/pancreatic claims as hypotheses, not facts.

How does it supposedly work?

The Khavinson school proposes that this small peptide binds DNA directly and regulates genes in pancreatic cells. That direct-DNA-binding gene-regulation idea is a single-school hypothesis, not mainstream-established molecular biology. What is actually shown is that the peptide can bind DNA/histones in binding assays — not a validated pancreatic gene-regulation effect.

Is there a known dose, and what form is it?

There is no citable human dose. The published work is animal, primate and review studies. There is also a chemical ambiguity worth noting: the specifications show the free-acid KEDW, but part of the literature describes the bioactive form as the amide KEDW-NH₂, which has a different mass. Any vendor mg amounts or 'courses' are unverified.

Is Pancragen approved or independently validated?

No. It is not approved by any major drug regulator, and no Western or independent group has reproduced the pancreatic or glucose-tolerance effects in a randomized trial. A separate Russian lab reported DNA/histone binding, but that corroborates only molecular binding, not pancreatic efficacy.

Primary sources

References

PMID 18642713Khavinson VKh et al., Bull Exp Biol Med 2007 — Pancragen effect on blood glucose, capillary permeability and adhesion in experimental-diabetes rats
PMID 18225766Kvetnoi IM et al., Bull Exp Biol Med 2007 — 'pancragene' effect on functional morphology of pancreas in experimental-diabetes rats
PMID 21246099Khavinson VKh et al., Bull Exp Biol Med 2010 — biological activity of endogenous Lys-Glu-Asp-Trp-NH₂ (KEDW-NH₂, the amide form)
PMID 25946840Goncharova ND et al., Advances in Gerontology 2014/2015 — Pancragen impact on endocrine pancreas and impaired glucose tolerance in old rhesus monkeys (primate model)
PMID 22448364Korkushko OV et al., Bull Exp Biol Med 2011 — prospects of Pancragen for correcting metabolic disorders in elderly people (human-oriented, prospects only)
PMID 23581987Fedoreyeva LI et al., Biochemistry (Moscow) 2013 — short peptides interact with FITC-labelled histones / oligonucleotide complexes (Vanyushin lab; partial-independent binding corroboration only)
PMID 24770759Tarnovskaya SI et al., Bull Exp Biol Med 2014 — molecular-mechanics modelling of DNA–tetrapeptide interactions
PMID 27909961Khavinson VK et al., Bull Exp Biol Med 2016 — 'Short Peptides Regulate Gene Expression' (single-school mechanism review)
PubChem CID 68452877PubChem record — identity (CID, formula, MW, sequence; free-acid KEDW). 'Pancragen'/'KEDW' are not PubChem synonyms — mapping is primary-sourced in the Khavinson literature

Research use only · Not medical advice · Updated 2026-06-01